Abstract
The implementation of nucleic acid testing in donor screening has improved the safety of tissue allografts. Although infectious disease transmission can be considered a rare event, the detection of occult hepatitis B infection remains challenging. The studies concerning this risk are mainly based on testing blood specimens. This work shows the correlation between results of samples obtained from donor blood and the corresponding tissue washing solution. Hepatitis B virus deoxyribonucleic acid was detected both in bone allografts from donors with serological profiles associated to active hepatitis B infection and occult hepatitis B infection. These results suggest that hepatitis B virus seems to concentrate in bone marrow even when a low viral load is present in peripheral blood. Even detection at molecular level is not enough to avoid the risk of hepatitis B virus transmission and a multiparametrical evaluation is required in tissue donor screening. The role of clinicians in recognition and reporting of allograft-associated infections is a major concern for the acquisition of experience to be applied in risk control of disease transmission.
Similar content being viewed by others
References
Arora S, Doda V, Kirtania T (2015) Sensitivity of individual donor nucleic acid testing (NAT) for the detection of hepatitis B infection by studying diluted NAT yield samples. Blood Transfus 13(2):227–232
Coen S, Angeletti C, Piselli P, Tronchin M, Vincenti D, Capobianchi MR, Galli C, Menzo S (2015) A statistical model based on serological parameters for predicting occult HBV infection: implications for organ/blood donations. New Microbiol 38(1):39–49
Commission Directive 2006/17/EC of 8 February 2006, implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells
Fishman JA, Greenwald MA, Grossi PA (2012) Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis 55(5):720–727
FitzSimons D, Hendrickx G, Vorsters A, Van Damme P (2013) Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17–18 November 2011. Vaccine 31(4):584–590
Fornés MG, Jiménez MA, Eisman M, Gómez Villagrán JL, Villalba R (2015) Nucleic acid-amplification testing for hepatitis B in cornea donors. Cell Tissue Bank 17(2):341–344
Heim A (2016) Evaluation of the ProcleixUltrio elite assay and the panther-system for individual NAT screening of blood, hematopoietic stem cell, tissue and organ donors. Transfus Med Hemother 43(3):177–182
Kim H, Lee SA, Kim DW, Lee SH, Kim BJ (2013) Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS ONE 8:e54486
Makvandi M (2016) Update on occult hepatitis B virus infection. World J Gastroenterol 22(39):8720–8734
Mallick TK, Mosquera A, Zinderman CE, StMartin L, Wise RP (2012) Reported infections after human tissue transplantation before and after new Food and Drug Administration (FDA) regulations, United States, 2001 through June, 2010. Cell Tissue Bank 13(2):259–267
Pruss A, Caspari G, Krüger DH, Blümel J, Nübling CM, Gürtler L, Gerlich WH (2010) Tissue donation and virus safety: more nucleic acid amplification testing is needed. Transpl Infect Dis 12(5):375–386
Raimondo G, Allain J-P, Brunetto MR et al (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652–657
Romanò L, Velati C, Cambiè G, Fomiatti L, Galli C, Zanetti AR, SIMTI Study Group for HBV Infection Among First-Time Blood (2013) Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus 11(2):281–288
Solves P, Mirabet V, Alvarez M, Vila E, Quiles F, Villalba JV, Montoro JA, Soler MA, Roig RJ (2008) Donor screening for hepatitis B virus infection in a cell and tissue bank. Transpl Infect Dis. 10(6):391–395
Solves P, Mirabet V, Alvarez M (2014) Hepatitis B transmission by cell and tissue allografts: how safe is safe enough? World J Gastroenterol 20(23):7434–7441
Wang D, Xie W, Chen T, Dong C, Zhao C, Tan H, Tian H, Xie Q (2015) Evaluation of the potential risk of hepatitis B virus transmission in skin allografting. Transplant Proc 47(6):1993–1997
World Health Organization (2015) Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. WHO, Geneva
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Mirabet, V., Álvarez, M., Luis-Hidalgo, M. et al. Detection of hepatitis B virus in bone allografts from donors with occult hepatitis B infection. Cell Tissue Bank 18, 335–341 (2017). https://doi.org/10.1007/s10561-017-9644-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-017-9644-3